Original Article

Comparison of The Effect of Subkojunctival Bevacizumab and Pegaptanib Sodium in an Experimental Corneal Neovascularisation Model - Original Article

  • Volkan Hürmeriç
  • Fazil Cüneyt Erdurman
  • Tarkan Mumcuoglu
  • Bülent Kurt
  • Ozan Dagli
  • Umut Karaca
  • Ali Hakan Durukan

Received Date: 22.06.2009 Accepted Date: 05.07.2009 Turk J Ophthalmol 2009;39(5):348-353

Purpose: To compare the effect of subconjunctival injection of bevacizumab and pegaptanib sodium on experimental corneal neovascularization in guinea pigs. Methods: Right eyes of twenty one guinea pigs were chemically cauterized. The subjects were divided into three groups. The first group (control group) received subconjunctival injection of balanced salt solution, the second group received subconjunctival injection of 1 mg bevacizumab, the third group received subconjunctival injection of 0.15 mg pegaptanib sodium simultaneously with cauterization. After determining the burn and neovascularization scores for all groups the animals were killed on the 10th day and histologic evaluation were performed. Results: There were no statistically significant differences in burn and neovascularisation scores between three groups (p= 0.173 and p= 0.082 respectively). The area of neovascularization at the cornea surface was 73.83±6.67% in the control group, 59.84±6.85% in the bevacizumab group and 82.96 ±5.59% in the pegaptanib group (p= 0.001). Histological examination show that the avarage number of corneal vessels were 13.05 ± 3.21 in the control group, 8.86 ± 2.89 in the bevacizumab group and 12.67 ± 2.04 in the pegaptanib group (p= 0.052). Conclusion: The antineovascular effect of bevacizumab is found to be higher than pegaptanib in the doses that we used in our experimental corneal neovascularisation model.

Keywords: Bevacizumab, Pegaptanib Sodium, Corneal Neovascularisation, Ginea Pigs

Full Text (Turkish)